Facilitated Percutaneous Coronary Intervention: Validating the open artery hypothesis

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. B, 2000, Pages

  Runyon, John P ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR;

DRUG ANTAGONISM; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR PATENCY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; HEART CATHETERIZATION; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; THROMBOLYTIC THERAPY; VASCULAR PATENCY; VENTRICULAR FUNCTION, LEFT;

EID: 0034146601     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
2. Anderson JL, Karagounis LA, Becker LC, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic and electrocardiographic evidence from the TEAM-3 study. Circulation 1993;87:1829-1839.
3. Lederink T, Simoons ML, Van Es GA, et al. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 1995;92:1110-1116.
4. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Study Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:162-168.
5. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA 1997;278:2093-2098.
6. Al-Mubarak N, Rogers WJ, Lambrew CT, et al. Consultation before thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1999;83:89-93.
7. Califf RM, Topol EJ, George BS, et al. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) I trial. Circulation 1988;77:1090-1099.
8. The TIMI Research Group. Immediate vs. delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. JAMA 1988;260:2849-2858.
9. Simoons ML, Betriu A, Col J, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-202.
10. Ross AM, Lundergan C, Rohrbeck SC, et al. Rescue angioplasty after failed thrombolysis: Technical and clinical outcomes in a large thrombolysis trial. J Am Coll Cardiol 1998;31:1511-1517.
11. Vaitkus PT, Laskey WK. Efficacy of adjunctive thrombolytic therapy in percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;24:1415-1423.
12. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992;86:1710-17.
13. Brodie BR, Stuckey T, Hansen C, et al. Benefit of reperfusion prior to intervention on outcomes after primary angioplasty for acute myocardial infarction (Abstr). Circulation 1998;98(Suppl 1):308.
14. Lundergan CF, Reiner JS, Coyne KS, et al. Effect of delay of successful reperfusion on ventricular function outcome the case for prior thrombolytic therapy with PTCA in acute myocardial function (Abstr). Circulation 1998;(Suppl 1):281.
15. Hanna GP, Bode C, Weaver D, et al. GUSTO III angiographic analysis: Acute coronary interventions may be the missing link to maintain the early patency advantage achieved with new generation thrombolytics (Abstr). Circulation 1998;98(Suppl 1):632.
16. Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741.
17. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
18. Miller JM, Ohman EM, Schildcrout JS, et al. Survival benefit of abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III trial (Abstr). J Am Coll Cardiol 1998;31(Suppl A):191.
19. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. Circulation 1999;99:2720-2732.
20. Hermann HC, Moliterno DJ, Bode C, et al. Combination abciximab and reduced-dose reteplase facilitates early PCI in acute MI: Results from the SPEED trial (Abstr). Circulation 1999;100(Suppl 1):188.